Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study

Objectives To evaluate the feasibility of a population-based screening trial using prostate-specific antigen (PSA), a kallikrein panel and multiparametric magnetic resonance imaging (MRI) aimed at minimizing overdiagnosis, while retaining mortality benefit. Patients and Methods Feasibility of the screening algorithm was evaluated in terms of participation, screening test results and cancer detection. A random sample of 400 men aged 65 years was identified from the population registry and invited for screening with three stepwise tests (PSA, kallikrein panel and MRI). Men with PSA levels >= 3 ng/mL were further tested with the kallikrein panel, and those with positive findings (risk >7.5%) were referred for prostate MRI. Men with positive MRI (Prostate Imaging Reporting and Data System [PI-RADS] score 3-5) had targeted biopsies only. Men with negative MRI, but PSA density >= 0.15 underwent systematic biopsies. Results Of the 399 men invited, 158 (40%) participated and 27 had PSA levels >= 3 ng/mL (7% of the invited and 17% of the participants). Of these, 22 had a positive kallikrein panel (6% of the invited and 81% of the PSA-positive men). Finally, 10 men (3% of the invited and 45% of 4Kscore [kallikrein panel]-positive) had a suspicious MRI finding (PI-RADS score >= 3) and five were diagnosed with a clinically significant prostate cancer (Gleason Grade Group [GG] >= 2) at fusion biopsy (3% of the participants), with two GG 1 cases (1%). Additional testing (kallikrein panel and MRI) after PSA reduced biopsies by 56%. Conclusion The findings constitute proof of principle for our screening protocol, as we achieved a substantial detection rate for clinically significant cancer with few clinically insignificant cases. Participation, however, was suboptimal.

Automated summary

This study evaluated the feasibility of a population-based screening trial using PSA, a kallikrein panel, and MRI. The findings showed that the screening protocol was able to minimize overdiagnosis while retaining mortality benefit, and achieved a substantial detection rate for clinically significant prostate cancer. However, participation rate needs improvement.